- Home
- GLPG vs TCBK Comparison
GLPG vs TCBK Comparison
Compare GLPG & TCBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- TCBK
- Stock Information
- Founded
- GLPG 1999
- TCBK 1975
- Country
- GLPG Belgium
- TCBK United States
- Employees
- GLPG N/A
- TCBK N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- TCBK Major Banks
- Sector
- GLPG Health Care
- TCBK Finance
- Exchange
- GLPG Nasdaq
- TCBK Nasdaq
- Market Cap
- GLPG 1.8B
- TCBK N/A
- IPO Year
- GLPG 2005
- TCBK N/A
- Fundamental
- Price
- GLPG $24.77
- TCBK $39.68
- Analyst Decision
- GLPG Sell
- TCBK Hold
- Analyst Count
- GLPG 5
- TCBK 5
- Target Price
- GLPG $26.75
- TCBK $50.75
- AVG Volume (30 Days)
- GLPG 159.3K
- TCBK 113.4K
- Earning Date
- GLPG 04-23-2025
- TCBK 04-24-2025
- Dividend Yield
- GLPG N/A
- TCBK 3.30%
- EPS Growth
- GLPG N/A
- TCBK N/A
- EPS
- GLPG 1.16
- TCBK 3.46
- Revenue
- GLPG $285,380,474.00
- TCBK $389,190,000.00
- Revenue This Year
- GLPG $0.08
- TCBK $8.08
- Revenue Next Year
- GLPG $0.23
- TCBK $5.63
- P/E Ratio
- GLPG $21.58
- TCBK $11.55
- Revenue Growth
- GLPG 14.99
- TCBK N/A
- 52 Week Low
- GLPG $22.36
- TCBK $31.73
- 52 Week High
- GLPG $32.17
- TCBK $51.06
- Technical
- Relative Strength Index (RSI)
- GLPG 38.92
- TCBK 33.84
- Support Level
- GLPG $24.48
- TCBK $39.94
- Resistance Level
- GLPG $25.72
- TCBK $41.57
- Average True Range (ATR)
- GLPG 0.51
- TCBK 1.12
- MACD
- GLPG -0.15
- TCBK -0.01
- Stochastic Oscillator
- GLPG 14.15
- TCBK 13.30
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.